Quintiles has established a leading position in conducting clinical studies and is now expanding its operations by opening new facilities

Quintiles India, a  fully integrated bio pharmaceutical services company offering clinical, commercial, consulting and capital solutions, registered a growth of 27 percent to touch an estimated sales revenue of 476.25 crore for 2010-11.

Looking at the growth of its services in India, Quintiles opened its new phase I research facility in Hyderabad, in January 2011. Constructed in partnership with the Apollo Group of Hospitals, the new facility will complement Quintiles’ existing phase I facilities around the globe to help customers navigate through complex early development challenges.

The Quintiles team in Hyderabad,  under the leadership of executive director, Dr Ashish Jain, will work in accordance to global standards and procedures and will be connected to sites in London, Uppsala and Kansas through Quintiles’ global data network. The 86-bed unit would evaluate compounds that are developed both in India and abroad. Data capture will be linked electronically to Quintiles’ other phase I units in UK, US, and Sweden. Furthermore, this unique phase I facility at Apollo Health City,  will house the offices of Quintiles and append to its operations in Ahmedabad, Bangalore, Delhi and Mumbai.

Several factors including, offices spread across the country, a well-established corporate infrastructure, government policies favoring R&D, growth in the health insurance sector, and availability of hospitals for trials are helping the company significantly.
Quintiles India has established a leading position with a track record of conducting clinical studies involving tens of thousands of patients in a variety of therapeutic areas. It offers various services such as, project management, clinical trial monitoring and site management, regulatory affairs, drug safety and pharmacovigilance, quality assurance, medical and scientific services.

Being the only global CRO in India, Quintiles’ study sites have been inspected by the US FDA. While conducting its studies, the firm follows the Quintiles Global Standard Operating Procedures and works in accordance to ICH GCP requirements. It has participated in FDA’s pivotal and supportive studies, with patient contribution from India accounting for eight percent to 75 percent of the data. Around 98 percent of the studies conducted by Quintiles India are for FDA or European regulatory bodies.

Quintiles’ Bangalore office offers world-class, end-to-end data management solutions, for paper as well as electronic CRFs. Quintiles provides services to the Central Cardiac Safety Laboratory from its offices in Mumbai and Bangalore. Since 2007, Quintiles has operated a CAP-accredited central clinical laboratory in Mumbai, which offers central lab services for Indian sites in global studies. This lab is a part of Quintiles global central lab network. All labs are connected through the proprietary Quintiles Laboratory Information Management System, which helps customers to operate and report seamlessly across the world.